Caring Ambassadors Hepatitis C Program Newsletter

www.HepCChallenge.org

August 2010

 

Clinical Trials, Cohort Studies, Pilot Studies

 

A sustained virologic response is durable in patients with chronic hepatitis C treated with peginterferon alfa-2a and ribavirin. Swain MG, Lai MY, Shiffman ML, et al. Gastroenterology. 2010 Jul 13. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/20637202

 

Retreatment of hepatitis C patients with pegylated interferon combined with ribavirin in non-responders to interferon plus ribavirin. Is it different in real life? Goncales FL Jr, Moma CA, Vigani AG, et al. BMC Infect Dis. 2010 Jul 20;10(1):212. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/20646277

 

Components of metabolic syndrome are independent predictors of mortality in patients with chronic liver disease: a population-based study. Stepanova M, Rafiq N, Younossi ZM.

Inova Health System Falls Church, Virginia, USA. Gut. 2010 Jul 26. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/20660697

 

Interferon reduces the risk of hepatocellular carcinoma in hepatitis C virus-related chronic hepatitis/liver cirrhosis. Masuzaki R, Yoshida H, Omata M. Oncology. 2010 Jul;78 Suppl 1:17-23. Epub 2010 Jul 8.

http://www.ncbi.nlm.nih.gov/pubmed/20616579

 

An updated follow-up of chronic hepatitis C after three decades of observation in pediatric patients cured of malignancy. Cesaro S, Bortolotti F, Petris MG, Brugiolo A, Guido M, Carli M. Pediatr Blood Cancer. 2010 Jul 15;55(1):108-12.

http://www.ncbi.nlm.nih.gov/pubmed/20127849

 

Peginterferon alpha-2a and ribavirin treatment of patients with haemophilia and hepatitis C virus infection: a single-centre study of 367 cases. Alavian SM, Tabatabaei SV, Keshvari M, et al. Liver Int. 2010 Jul 8. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/20629950

 

Hyperinsulinaemia reduces the 24-h virological response to PEG-interferon therapy in patients with chronic hepatitis C and insulin resistance. Bortoletto G, Scribano L, Realdon S, et al. J Viral Hepat. 2010 Jul;17(7):475-80.

http://www.ncbi.nlm.nih.gov/pubmed/19878535

 

Influence of alpha-1 antitrypsin heterozygosity on treatment efficacy of HCV combination therapy. Kok KF, van Soest H, van Herwaarden AE, et al. Eur J Gastroenterol Hepatol. 2010 Jul;22(7):808-12.

http://www.ncbi.nlm.nih.gov/pubmed/19794310

 

Is irritable bowel syndrome associated with chronic hepatitis C? Fouad YM, Makhlouf MM, Khalaf H, et al. J Gastroenterol Hepatol. 2010 Jul;25(7):1285-8.

http://www.ncbi.nlm.nih.gov/pubmed/20594257

 

Reinfection with hepatitis C virus following sustained virological response in injection drug users. Grebely J, Knight E, Ngai T, et al. J Gastroenterol Hepatol. 2010 Jul;25(7):1281-4.

http://www.ncbi.nlm.nih.gov/pubmed/20594256

 

High prevalence of late relapse and reinfection in prisoners treated for chronic hepatitis C.

Bate JP, Colman AJ, Frost PJ, Shaw DR, Harley HA. J Gastroenterol Hepatol. 2010 Jul;25(7):1276-80.

http://www.ncbi.nlm.nih.gov/pubmed/20594255

 

Randomized trial of albinterferon alfa-2b for the treatment of patients with chronic hepatitis C Virus Genotype 2 or 3. Nelson DR, Benhamou Y, Chuang WL, et al. Gastroenterology. 2010 Jul 2. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/20600017

 

Randomized trial of albinterferon alfa-2b for the treatment of patients with chronic hepatitis c virus genotype 1. Zeuzem S, Sulkowski MS, Lawitz EJ, et al. Gastroenterology. 2010 Jul 2. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/20600013

 

Meta-analysis shows extended therapy improves response of patients with chronic hepatitis C virus genotype 1 infection. Farnik H, Lange CM, Sarrazin C, et al. Clin Gastroenterol Hepatol. 2010 Jul 2. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/20601130

 

Basic and Applied Science, Pre-Clinical Studies

 

Impairment of TLR7-dependent signaling in dendritic cells from chronic hepatitis C virus (HCV)-infected non-responders to interferon/ribavirin therapy. Simone O, Tortorella C,

http://www.ncbi.nlm.nih.gov/pubmed/20390327

 

Safety and immunogenicity of HCV E1E2 vaccine adjuvanted with MF59 administered to healthy adults. Frey SE, Houghton M, Coates S, et al. Vaccine. 2010 Jul 6. [Epub ahead of print] Abrignani S, Chien D, Rosa D, et al. Vaccine. 2010 Jul 6. [Epub ahead of print]

 

Ratio of HCV structural antigens in protein-based vaccine formulations is critical for functional immune response induction. Martínez-Donato G, Musacchio A, Alvarez-Lajonchere L, et al. Biotechnol Appl Biochem. 2010 Jul 9;56(3):111-8.

http://www.ncbi.nlm.nih.gov/pubmed/20515441

 

 

A polymorphism near IL28B is associated with spontaneous clearance, of acute hepatitis C virus and jaundice. Tillmann HL, Thompson AJ, Patel K, et al. Gastroenterology. 2010 Jul 13. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/20637200

 

ITPA polymorphism affects ribavirin-induced anemia and outcome of therapy - a Genome-wide study of Japanese HCV patients. Ochi H, Maekawa T, Abe H, et al. Gastroenterology. 2010 Jul 13. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/20637204

 

Adaptation of hepatitis C virus to mouse CD81 permits infection of mouse cells in the absence of human entry factors. Bitzegeio J, Bankwitz D, Hueging K, et al. PLoS Pathog. 2010 Jul 1;6:e1000978.

http://www.ncbi.nlm.nih.gov/pubmed/20617177

 

Heat shock protein 72 is associated with the hepatitis C virus replicase complex and enhances viral RNA replication. Chen YJ, Chen YH, Chow LP, et al. J Biol Chem. 2010 Jul 2. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/20601427

 

HIV/HCV/HBV Coinfection

 

Hepatitis C virus infection is associated with endothelial dysfunction in HIV/hepatitis C virus coinfected patients. Castro IF, Micheloud D, Berenguer J, et al. AIDS. 2010 Jul 7. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/20616694

 

Treatment of hepatitis C in HCV mono-infected and in HIV-HCV co-infected patients: an open-labelled comparison study. Gonvers JJ, Heim MH, Cavassini M, et al. Swiss Med Wkly. 2010 Jul 19;140:w13055. doi: 10.4414/smw.2010.13055.

http://www.ncbi.nlm.nih.gov/pubmed/20648398

 

HBsAg profiles in patients receiving peginterferon alfa-2a plus ribavirin for the treatment of dual chronic infection with hepatitis B and C viruses. Yu ML, Lee CM, Chuang WL, et al. J Infect Dis. 2010 Jul 1;202(1):86-92.

http://www.ncbi.nlm.nih.gov/pubmed/20482252

 

Management of HIV and hepatitis virus coinfection. Mendes-Corrêa M, Núñez M. Expert Opin Pharmacother. 2010 Jul 14. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/20629586

 

Hepatic steatosis in patients coinfected with human immunodeficiency virus/hepatitis C virus: a meta-analysis of the risk factors. Machado MV, Oliveira AG, Cortez-Pinto H. Hepatology. 2010 Jul;52(1):71-8.

http://www.ncbi.nlm.nih.gov/pubmed/20578130

 

Interobserver concordance in the assessment of liver fibrosis in HIV/HCV-coinfected patients using transient elastometry. Neukam K, Recio E, Camacho A, et al. Eur J Gastroenterol Hepatol. 2010 Jul;22(7):801-7.

http://www.ncbi.nlm.nih.gov/pubmed/19773664

 

Effect of control selection on sustained viral response rates in genotype 2/3 HCV mono-infected versus HIV/HCV co-infected patients. Nilsson J, Weiland O. Scand J Infect Dis. 2010 Jul;42(6-7):533-9.

http://www.ncbi.nlm.nih.gov/pubmed/20214543

 

Prevalence and correlates of co-infection with human immunodeficiency virus and hepatitis C virus in male injection drug users in Iran. Hosseini M, SeyedAlinaghi S, Kheirandish P, et al. Arch Iran Med. 2010 Jul;13(4):318-23.

http://www.ncbi.nlm.nih.gov/pubmed/20597566

 

Prevalence of hepatitis C virus and hepatitis B virus infections in HIV-positive Chinese patients. Yan YX, Gao YQ, Sun X, et al. Epidemiol Infect. 2010 Jul 2:1-7. [Epub ahead of print]

Wang W, Huang XJ, Zhang T, Li M, Zang CP, Li ZC, Wu H.

http://www.ncbi.nlm.nih.gov/pubmed/20598209

 

Impact of hepatitis C viral replication on CD4+ T-lymphocyte progression in HIV-HCV coinfection before and after antiretroviral therapy. Potter M, Odueyungbo A, Yang H, et al. AIDS. 2010 Jul 31;24(12):1857-65.

http://www.ncbi.nlm.nih.gov/pubmed/20479633

 

Hepatitis C infection in HIV-1 natural viral suppressors. Sajadi MM, Shakeri N, Talwani R, Redfield RR. AIDS. 2010 Jul 17;24(11):1689-95.

http://www.ncbi.nlm.nih.gov/pubmed/20467290

 

IP-10 predicts the first phase decline of HCV RNA and overall viral response to therapy in patients co-infected with chronic hepatitis C virus infection and HIV. Falconer K, Askarieh G, Weis N, et al. Scand J Infect Dis. 2010 Jul 7. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/20608766

 

Acute hepatitis C in HIV-infected men who have sex with men: an emerging sexually transmitted infection. van de Laar TJ, Matthews GV, Prins M, Danta M. AIDS. 2010 Jul 31;24(12):1799-812.

http://www.ncbi.nlm.nih.gov/pubmed/20601854

 

Cellular immune responses to HCV core increase and HCV RNA levels decrease during successful antiretroviral therapy. Rohrbach J, Robinson N, Harcourt G, et al. Gut. 2010 Jul 26. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/20660698

 

Changes in liver stiffness in patients with chronic hepatitis C with and without HIV co-infection treated with pegylated interferon plus ribavirin. Macías J, Del Valle J, Rivero A, et al. J Antimicrob Chemother. 2010 Jul 22. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/20656678

 

Hepatitis C transmission, prevention, and treatment knowledge among patients with HIV.

Proeschold-Bell RJ, Blouin R, Reif S, et al. South Med J. 2010 Jul;103(7):635-41.

http://www.ncbi.nlm.nih.gov/pubmed/20531062

 

Complementary and Alternative Medicine

 

Vitamin D supplementation improves response to antiviral treatment for recurrent hepatitis C. Bitetto D, Fabris C, Fornasiere E, Transpl Int. 2010 Jul 22. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/20649944

 

Diagnostics, Epidemiology, and Miscellaneous Works

 

Determining rates of hepatitis C in a clozapine treated cohort. Sockalingam S, Shammi C, Powell V, Barker L, Remington G. Schizophr Res. 2010 Jul 5. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/20605572

 

Liver fibrosis in chronic hepatitis C virus infection: differentiating minimal from intermediate fibrosis with perfusion CT. Ronot M, Asselah T, Paradis V, et al. Radiology. 2010 Jul;256(1):135-42.

http://www.ncbi.nlm.nih.gov/pubmed/20574090

 

Direct detection of unamplified hepatitis C virus RNA using unmodified gold nano-particles. Shawky SM, Bald D, Azzazy HM. Clin Biochem. 2010 Jul 19. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/20627095

 

Early viral and peripheral blood mononuclear cell responses to pegylated interferon and ribavirin treatment: the first 24 h. Devitt E, Lawless MW, Sadlier D, et al. Eur J Gastroenterol Hepatol. 2010 Jul 13. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/20631625

 

Hepatic fibrosis in patients with chronic hepatitis C assessed by transient elastography: implications for determining the efficacy of antiviral therapy. Mendoza J, Trapero-Marugán M, González-Moreno L, et al. Rev Esp Enferm Dig. 2010 Jul;102(7):426-34.

http://www.ncbi.nlm.nih.gov/pubmed/20617863

 

MELD Era: Is this time to replace the original Child-Pugh score in patients with de-compensated cirrhosis of liver. Shaikh S, Ghani H, Memon S, Baloch GH, Jaffery M, Shaikh K. J Coll Physicians Surg Pak. 2010 Jul;20(7):432-5.

http://www.ncbi.nlm.nih.gov/pubmed/20642940

 

Hepatitis C virus prevalence and clearance among US Blood Donors, 2006-2007: associations with birth cohort, multiple pregnancies, and body mass index. Murphy EL, Fang J, Tu Y, et al. J Infect Dis. 2010 Jul 9. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/20617929

 

Alcohol and hepatitis C virus-interactions in immune dysfunctions and liver damage.

Szabo G, Wands JR, Eken A, et al. Alcohol Clin Exp Res. 2010 Jul 1. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/20608905

 

Emerging therapies for hepatitis C virus. Birerdinc A, Younossi ZM. Expert Opin Emerg Drugs. 2010 Jul 15. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/20629602

 

Direct economic burden of chronic hepatitis C virus in a United States managed care population. Davis KL, Mitra D, Medjedovic J, Beam C, Rustgi V. J Clin Gastroenterol. 2010 Jul 10. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/20628308

 

Viral pathogens. Ragni MV, Sherman KE, Jordan JA. Haemophilia. 2010 Jul;16 Suppl 5:40-6.

http://www.ncbi.nlm.nih.gov/pubmed/20590855

 

Pharmacy participation in non-prescription syringe sales in Los Angeles and San Francisco Counties, 2007. Cooper EN, Dodson C, Stopka TJ, Riley ED, Garfein RS, Bluthenthal RN. J Urban Health. 2010 Jul;87(4):543-52.

http://www.ncbi.nlm.nih.gov/pubmed/20549568

 

Population risk of syringe reuse: estimating the probability of transmitting bloodborne disease. Sikora C, Chandran AU, Joffe AM, Johnson D, Johnson M. Infect Control Hosp Epidemiol. 2010 Jul;31(7):748-54.

http://www.ncbi.nlm.nih.gov/pubmed/20509761

 

Use of gloves and reduction of risk of injury caused by needles or sharp medical devices in healthcare workers: Results from a case-crossover study. Kinlin LM, Mittleman MA, Harris AD, Rubin MA, Fisman DN. Infect Control Hosp Epidemiol. 2010 Jul 26. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/20658920

 

Sex and age differences in lipid response to chronic infection with the hepatitis C virus in the United States National Health and Nutrition Examination Surveys.

Lao XQ, Thompson A, McHutchison JG, McCarthy JJ. J Viral Hepat. 2010 Jul 19. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/20642483

 

Development of the hepatitis C self-management program. Groessl EJ, Weingart KR, Gifford AL, Asch SM, Ho SB. Patient Educ Couns. 2010 Jul 15. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/20638216

 

Implications of hepatitis C virus infection for behavioral symptoms and activities of daily living. Posada C, Moore DJ, Woods SP, et al. J Clin Exp Neuropsychol. 2010 Jul;32(6):637-44.

http://www.ncbi.nlm.nih.gov/pubmed/20603743